Compare Incyte Corporation (INCY) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Lufax Holding Ltd — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.99B), while Lufax Holding Ltd trades at $0.96 (market cap $1.01B). The key difference: Incyte Corporation is far larger — about 22.8× Lufax Holding Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Lufax Holding Ltd for 13 Days on average.
| INCY | LU | |
|---|---|---|
Market Cap | $22.99B | $1.01B |
Volume | 1,274,487 | 4,754,976 |
Sector | Health | Financials |
52-Week High | $129.93 | $3.93 |
52-Week Low | $83.80 | $0.95 |
Typical Hold Time | 33 Days | 13 Days |
Enterprise Value | $18.50B | $59.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $112.75, up 0.02% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported strong Q2 2026 earnings, beating expectations with EPS of $3.09 versus $2.15, and revenue growth from $5.14B in 2025 to a projected $5.8B in 2026. Recent FDA approval for Atebrioz and a strategic push for post-JAKAFI growth highlight pipeline progress. Valuation ratios appear reasonable with a P/E of 14.45 and EV/EBITDA of 8.94.
Outlook is positive with a consensus price target of $132.07, implying 17% upside, supported by 52% analyst buy ratings. Risks include reliance on JAKAFI, which loses exclusivity after 2029, and near-term earnings volatility as seen in the Q4 2025 miss. Strong cash flow and profitability metrics suggest resilience, but execution on pipeline diversification is critical for sustained growth.
LU trades at $0.98, down 2.83% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported a net loss of $2.10 billion on $23.11 billion revenue in 2025, with negative profit margins and declining revenue trends. Recent corporate actions include a 10:1 reverse stock split effective October 2026. Analyst consensus remains predominantly bullish with 69% buy ratings, citing deep value potential despite ongoing operational challenges.
LU presents a high-risk, event-driven opportunity with significant valuation discounts (P/S 0.26, P/B 0.07) but faces substantial execution risks amid regulatory pressures and persistent losses. The stock's outlook hinges on successful restructuring and potential Hong Kong listing catalysts, though near-term headwinds from China's consumer lending sector remain challenging for profitability recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
